Model endpoints were either benign FNA results or definitive histological diagnosis.Molecular testing added $104 per patient to the overall cost of nodule evaluation (StC $578 vs. MT $682).
After fitting the model, endpoints were computed by finding where the OD curves for each antigen type crossed the OD curve for two times the negative control values at each serum dilution.
We analyzed the benefit of adjuvant CMF and anthracyclines in univariate and multivariable survival models; endpoints were disease-free (DFS) and overall survival (OS).
In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).
Studies were included if they met the following criteria: the study presented at least one formal prediction model or an update on a previously developed model; the endpoint was incident type 2 diabetes in a longitudinal design; and the population had to be at least partly white because the EPIC-NL cohort to be used for validation consists predominantly of white adults.
Change over time in growth-related endpoints was tested using linear mixed-effect models (to model change in endpoints over 3 years of therapy).
To assign values to the model, there were two health endpoints being modeled and two employment-related endpoints.
Our models for two endpoints are located at upper left corner and on the top of all other models displayed in the graphs (For BR_D_Model, MCC = 0.707, Val_MCC = 0.395, Std_Dev = 0.030; For BR_E_Model, MCC = 0.904, Val_MCC = 0.819, Std_Dev = 0.029) (Table 2 and Figure 3).
These three regulatory uses can each require the use of different QSAR models, because different endpoints are addressed, and because different levels/kinds of certainty are required.
Models for continuous endpoints are typically estimated via nonlinear least-squares procedures.
